PPMI Publications

Publication of PPMI data is a major goal of the PPMI Steering Committee, the Industry Scientific Advisory Board, and the study sponsor, The Michael J Fox Foundation for Parkinson’s Research. Select publications will be posted to the website.  There are two categories of PPMI publications as defined below:

  • Primary Publications: Authored by the Steering Committee, Investigators, Study Cores and Working Groups, reflecting the contribution of those authors. “And The Parkinson’s Progression Markers Initiative*” will be written on the author line of the manuscript with an asterisk referring to the list of names of individuals identified on the PPMI Author List. The author list must be include as an appendix to ensure that all authors may be cited. All Primary Publications must collaborate with the PPMI Statistics Core and must be sent to both the PPMI Steering Committee and the PPMI DPC for review prior to journal submission.
  • Publications Utilizing PPMI Data: It is expected that investigators outside of the study will conduct research and seek to publish analyses using PPMI data and specimens. These individuals are encouraged to publish novel scientific findings that result from their research using PPMI. Authorship of such a publication will not include PPMI in the author line, but will acknowledge PPMI personnel and PPMI funding support as detailed in the PPMI Publications Policy and must be sent to the PPMI DPC for administrative review prior to journal submission.


Displaying 78 publication(s).


Primary PPMI Publications

Title Author(s) Citation Keyword(s) PMID
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson’s Progression Marker Initiative Acta Neuropathol. 2016 Mar 28. [Epub ahead of print] Alpha-synuclein; A?1-42; Cerebrospinal fluid biomarker; Parkinson’s Progression Markers Initiative; Parkinson’s disease; Tau 27021906
How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K; PPMI Investigators. 2016 Apr 23. pii: S1353-8020(16)30131-6. doi: 10.1016/j.parkreldis.2016.04.027. [Epub ahead of print] Disease subtypes; Gait disorder predominant; Parkinson's disease; Postural instability; Tremor dominant 27132498
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Weintraub D; Simuni T; Caspell-Garcia C; Coffey C; Lasch S; Siderowf A; Aarsland D; Barone P; Burn D; Chahine LM; Eberling J; Espay AJ; Foster ED; Leverenz JB; Litvan I; Richard I; Troyer MD; Hawkins KA; and the Parkinson\'s Progression Markers Initiative Mov Disord. 2015 Mar 4. doi: 10.1002/mds.26170. [Epub ahead of print] anxiety; apathy; cognition; depression; impulse control disorder; psychosis 25737166
Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study Simuni, T; Caspell-Garcia, C; Coffey, C; Chahine, L; Lasch, S; Oertel, W; Mayer, G; Högl, B; Postuma, R; Videnovic, A; Amara, AW; Marek, K; and for the PPMI Sleep Working group on behalf of the PPMI Investigators Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26248. [Epub ahead of print] daytime somnolence; biomarkers; daytime sleepiness; nonmotor symptoms; sleep 26095202
Association of Cerebrospinal Fluid B-Amyloid 1-42, T-tau, P-tau181, and a-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM; and the Parkinson’s Progression Markers Initiative. JAMA Neurol. 2013 Oct;70(10):1277-87. alpha-synuclein; amyloid beta; tau; cerebrospinal fluid; CSF; phenotype 23979011
The Parkinson Progression Marker Initiative (PPMI). Parkinson Progression Marker Initiative Prog. Neurobiol. 2011 Dec;95(4):629-35. biomarker; dopamine transporter imaging; diffusion tensor imaging; cerebrospinal fluid; alpha synuclein 21930184
Multiple Modality Biomarker Prediction of Cognitive Impairment in Prospectively Followed de novo Parkinson Disease Chelsea Caspell-Garcia, Tanya Simuni, Norbert Schuff, Duygu Toson-Turgut, I-Wei Wu, Yu Zhang, Mike Nalls, Andrew Singleton, Leslie A. Shaw, Ju-Hee Kang, John Q. Trojanowski, Andrew Siderowf, Christopher Coffey, Shirley Lasch, Dag Aarsland, David Burn, Lama M. Chahine, Jamie Eberling, Alberto J. Espay, Eric D. Foster, Keith A. Hawkins, Irene Litvan, Irene Richard, Daniel Weintraub, and the Parkinson\'s Progression Markers Initiative PLoS One. 2017 May 17;12(5):e0175674. 28520803
Predictors of Time to Initiation of Symptomatic Therapy in Early Parkinson's Disease Tanya Simuni, Jeff Long, Chelsea Caspell-Garcia, Christopher Coffey, and Ken Marek on behalf of the PPMI Investigators 2015 Biomarkers, Symptomatic Therapy 27386498
Novel Recruitment Strategy to Enrich for LRRK2 Mutation Carriers Tatiana Foroud, Ph.D.1, Danielle Smith, B.S.1, Jacqueline Jackson, B.S.1, Jennifer Verbrugge, M.S.1, Cheryl Halter,M.S.1, Katherine Sims, M.D.2, Winnie Xin, Ph.D.2, Vanessa Arnedo, M.P.H. 3, Shirley Lasch, B.S., M.B.A., 4, Ken Marek, M.D.4 and the Parkinson\'s Progression Markers Initiative 2014 LRRK2, recruitment 26436106


Publications Using PPMI Data

Title Author(s) Citation Keyword(s) PMID
Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson’s Disease Patients Simon Buatois, Sylvie Retout, Nicolas Frey, Sebastian Ueckert Buatois, S., Retout, S., Frey, N. et al. Pharm Res (2017) 34: 2109. https://doi.org/10.1007/s11095-017-2216-1 drug effect, item response theory, MDS-UPDRS, Parkinson’s disease, pharmacometrics 22300470
The influence of vascular risk factors on cognitive function in early Parkinson's disease. Doiron M, Langlois M, Dupré N, Simard M. Int J Geriatr Psychiatry. 2017 May 16. doi: 10.1002/gps.4735. [Epub ahead of print] 28509343
Distinct Role of Striatal Functional Connectivity and Dopaminergic Loss in Parkinson’s Symptoms Juergen Dukart, Fabio Sambataro and Alessandro Bertolino Frontiers Aging Neurosci 2017, May. 9:151. doi: 10.3389/fnagi.2017.00151 28588475
Voxel-based Logistic Analysis of PPMI Control and Parkinson's Disease DaTscans Hemant D. Tagare, Christine DeLorenzo, Sudhakar Chelikani, Lawrence Saperstein, Robert K. Fulbright NeuroImage. 2017 May;152:299-311 Parkinson's disease; DaTscan; PPMI; Logistic Lasso; Logistic Principal Components 28254511
Diagnostic Accuracy and Confidence in the Clinical Detection of Cognitive Impairment in Early-Stage Parkinson Disease. Wyman-Chick KA; Martin PK; Barrett MJ; Manning CA; Sperling SA; J Geriatr Psychiatry Neurol 2017 May;30(3):178-183 28351200
Portable objective assessment of upper extremity motor function in Parkinson's disease. Chahine LM; Uribe L; Hogarth P; McNames J; Siderowf A; Marek K; Jennings D; Parkinsonism Relat. Disord. 2017 Jul;(): 28747279
Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB; Brain 2017 Jul;140(7):1959-1976 28549077
Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study. Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC; Mov. Disord. 2017 Jul;32(7):1066-1073 28548309
Evaluating the Performance of the Montreal Cognitive Assessment in early stage Parkinson's disease. Kletzel, S.L., Hernandez, J.M., Miskiel, E.F., Mallinson, T., Pape, T.L. Parkinsonism Relat Disord. 2017 Jan 28. pii: S1353-8020(17)30029-9. doi: 10.1016/j.parkreldis.2017.01.012. 28189463
Does apolipoprotein A1 predict microstructural changes in subgenual cingulum in early Parkinson? Rahmani F; Aarabi MH; J. Neurol. 2017 Feb;(): 28168521
Aging modifies the effect of GCH1 RS11158026 on DAT uptake and Parkinson's disease clinical severity. Webb J; Willette AA; Neurobiol. Aging 2017 Feb;50():39-46 27871051
Latent Cognitive Phenotypes in De Novo Parkinson's Disease: A Person-Centered Approach. LaBelle DR; Walsh RR; Banks SJ; J Int Neuropsychol Soc 2017 Aug;23(7):551-563 28651678
Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. Amara AW; Chahine LM; Caspell-Garcia C; Long JD; Coffey C; Högl B; Videnovic A; Iranzo A; Mayer G; Foldvary-Schaefer N; Postuma R; Oertel W; Lasch S; Marek K; Simuni T; Parkinson’s Progression Markers Initiative; J. Neurol. Neurosurg. Psychiatr. 2017 Aug;88(8):653-662 28554959
Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. Ffytche DH, Pereira JB, Ballard C1, Chaudhuri KR, Weintraub D, Aarsland D. J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):325-331. doi: 10.1136/jnnp-2016-314832. 28315846
Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson’s Disease Clinical Trials: A Disease Progression Modeling Analysis Daniela J. Conrado1,∗, Timothy Nicholas2, Kuenhi Tsai3, Sreeraj Macha3, Vikram Sinha3, Julie Stone3, Brian Corrigan2, Massimo Bani4, Pierandrea Muglia1, Ian A. Watson5, Volker D. Kern1, Elena Sheveleva1,6, Kenneth Marek7, Diane T. Stephenson1 and Klaus Romero1 on behalf of the Critical Path for Parkinson’s (CPP) Parkinson’s Disease Modeling and Simulation Working Group ClinTranslSci. 2017 Jul;00:1–8 28749580
A test-retest study on Parkinson's PPMI dataset yields statistically significant white matter fascicles. Cousineau M; Jodoin PM; Morency FC; Rozanski V; Grand\'Maison M; Bedell BJ; Descoteaux M; Neuroimage Clin 2017 ;16():222-233 28794981
Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease. Santiago JA, Littlefield AM, Potashkin JA. Sci Rep. 2016 Sep 29;6:34579. doi: 10.1038/srep34579. transcriptomics, biomarker 27680512
Joint feature-sample selection and robust diagnosis of Parkinson's disease from MRI data. Adeli E; Shi F; An L; Wee CY; Wu G; Wang T; Shen D; Neuroimage 2016 Nov;141():206-19 27296013
Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder Chahine LM, Xie SX, Simuni T, Tran B, Postuma R, Amara A, Oertel WH, Iranzo A, Scordia C, Fullard M, Linder C, Purri R, Darin A, Rennert L, Videnovic A, Del Riva P, Weintraub D. Parkinsonism Relat Disord. 2016 Mar 12. pii: S1353-8020(16)30060-8. doi: 10.1016/j.parkreldis.2016.03.006. [Epub ahead of print] Cognition; Dementia; REM sleep behavior disorder 27010070
High-Accuracy Detection of Early Parkinson's Disease through Multimodal Features and Machine Learning Prashanth R, Dutta Roy S, Mandal PK, Ghosh S. Int J Med Inform. 2016 Jun;90:13-21. doi: 10.1016/j.ijmedinf.2016.03.001. Epub 2016 Mar 5. Computer-aided diagnosis; Parkinson’s disease; cerebrospinal fluid markers; dopaminergic imaging; non-motor features; pattern classification 27103193
High Accuracy Classification of Parkinson's Disease through Shape Analysis and Surface Fitting in 123I-Ioflupane SPECT Imaging Prashanth R, Dutta Roy S, Mandal PK, Ghosh S. IEEE J Biomed Health Inform. 2016 Mar 29. [Epub ahead of print] Scans Without Evidence of Dopaminergic Deficit (SWEDD), Single Photon Emission Computed Tomography (SPECT), Striatal Binding Ratio (SBR)-based features, Support Vector Machine (SVM) classifier 27101625
Predictors of time to initiation of symptomatic therapy in early Parkinson's disease. Simuni T; Long JD; Caspell-Garcia C; Coffey CS; Lasch S; Tanner CM; Jennings D; Kieburtz KD; Marek K; PPMI Investigators; Ann Clin Transl Neurol 2016 Jul;3(7):482-94 27386498
Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. Davis AA, Andruska KM, Benitez BA, Racette BA, Perlmutter JS, Cruchaga C. Neurobiol Aging. 2016 Jan;37:209.e1-7. doi: 10.1016/j.neurobiolaging.2015.09.014. Epub 2015 Sep 30. Age at onset; GBA; MAPT; Motor progression; Parkinson disease; SNCA 26601739
Overlap between Parkinson disease and Alzheimer disease in ABCA7 functional variants Nuytemans K, Maldonado L, Ali A, John-Williams K, Beecham GW, Martin E, Scott WK, Vance JM. Neurol Genet. 2016 Jan 14;2(1):e44. doi: 10.1212/NXG.0000000000000044. eCollection 2016. ATP-binding cassette transporter A7 (ABCA7), whole-exome sequencing, 27066581
Neural substrates of excessive daytime sleepiness in early drug naïve Parkinson's disease: A resting state functional MRI study. Wen MC; Ng SY; Heng HS; Chao YX; Chan LL; Tan EK; Tan LC Parkinsonism Relat Disord. 2016 Jan 12. pii: S1353-8020(16)30012-8. 26810915
Age at onset and Parkinson disease phenotype Pagano G, Ferrara N, Brooks DJ, Pavese N. 2016 Feb 10. pii: 10.1212/WNL.0000000000002461. [Epub ahead of print] biomarkers, DaTSCAN imaging, age of onset 26865518
COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. Santos-García D; Mir P; Cubo E; Vela L; Rodríguez-Oroz MC; Martí MJ; Arbelo JM; Infante J; Kulisevsky J; Martínez-Martín P; COPPADIS Study Group; BMC Neurol 2016 Feb;16():26 26911448
Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease Kraemmer J, Smith K, Weintraub D, Guillemot V, Nalls MA, Cormier-Dequaire F, Moszer I, Brice A, Singleton AB, Corvol JC. J Neurol Neurosurg Psychiatry. 2016 Apr 13. pii: jnnp-2015-312848. doi: 10.1136/jnnp-2015-312848. [Epub ahead of print] Impulse control disorders, dopamine replacement therapy, ICD heritability 27076492
Olfactory impairment predicts cognitive decline in early Parkinson's disease. Fullard ME; Tran B; Xie SX; Toledo JB; Scordia C; Linder C; Purri R; Weintraub D; Duda JE; Chahine LM; Morley JF; Parkinsonism Relat. Disord. 2016 Apr;25():45-51 26923521
CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report. Gao R; Zhang G; Chen X; Yang A; Smith G; Wong DF; Zhou Y; PLoS ONE 2016 ;11(10):e0164762 27764160
Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments. Rahmim A; Salimpour Y; Jain S; Blinder SA; Klyuzhin IS; Smith GS; Mari Z; Sossi V; Neuroimage Clin 2016 ;12():e1-e9 27995072
Progression of Regional Microstructural Degeneration in Parkinson's Disease: A Multicenter Diffusion Tensor Imaging Study. Zhang Y; Wu IW; Tosun D; Foster E; Schuff N; Parkinson’s Progression Markers Initiative; PLoS ONE 2016 ;11(10):e0165540 27798653
Network structure of brain atrophy in de novo Parkinson's disease Zeighami Y, Ulla M, Iturria-Medina Y, Dadar M, Zhang Y, Larcher KM, Fonov V, Evans AC, Collins DL, Dagher A. Elife. 2015 Sep 7;4. doi: 10.7554/eLife.08440 MRI; basal ganglia; deformation-based morphometry; human; independent component analysis; neuroscience; substantia nigra 26344547
CSF ?-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease. Terrelonge M; Marder KS; Weintraub D; Alcalay RN; J. Mol. Neurosci. 2015 Sep. doi 10.1007/s12031-015-0647-x [Epub ahead of print] CSF beta-amyloid 1-42; cognitive impairment 26330275
Graph-theory-based spectral feature selection for computer aided diagnosis of Parkinson's disease using T1-weighted MRI Rana B; Juneja A; Saxena M; Gudwani S; Kumaran SS; Behari M; Agrawal RK Int J Imag Syst Tech. 2015 Sep;25(3):245-55. computer-aided diagnosis; magnetic resonance imaging; spectral feature selection
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Nalls MA; McLean CY; Rick J; Eberly S; Hutten SJ; Gwinn K; Sutherland M; Martinez M; Heutink P; Williams NM; Hardy J; Gasser T; Brice A; Price TR; Nicolas A; Keller MF; Molony C; Gibbs JR; Chen-Plotkin A; Suh E; Letson C; Fiandaca MS; Mapstone M; Federoff HJ; Noyce AJ; Morris H; Van Deerlin VM; Weintraub D; Zabetian C; Hernandez DG; Lesage S; Mullins M; Conley ED; Northover CA; Frasier M; Marek K; Day-Williams AG; Stone DJ; Ioannidis JP; Singleton AB; Parkinson\'s Disease Biomarkers Program and Parkinson\'s Progression Marker Initiative investigators; Lancet Neurol 2015 Oct;14(10):1002-9 26271532
Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients. Santiago JA, Potashkin JA PLoS One. 2015 Nov 13;10(11):e0142582. doi: 10.1371/journal.pone.0142582. eCollection 2015. 26566043
Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease Smith KM, Xie SX, Weintraub D J Neurol Neurosurg Psychiatry. 2015 Nov 3. pii: jnnp-2015-311827. doi: 10.1136/jnnp-2015-311827 Impulse control disorder; dopamine transported imaging; DaT 26534930
Computer-Aided Diagnosis of Parkinson's Disease Using Enhanced Probabilistic Neural Network Hirschauer TJ, Adeli H, Buford JA. J Med Syst. 2015 Nov;39(11):179. doi: 10.1007/s10916-015-0353-9. Epub 2015 Sep 29. Computer-aided diagnosis; Enhanced probabilistic neural networks; Parkinson’s disease 26420585
Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease Stephenson D, Hu MT, Romero K, Breen K, Burn D, Ben-Shlomo Y, Bhattaram A, Isaac M, Venuto C, Kubota K, Little MA, Friend S, Lovestone S, Morris HR, Grosset D, Sutherland M, Gallacher J, Williams-Gray C, Bain LJ, Avilés E, Marek K, Toga AW, Stark Y, Forrest Gordon M, Ford S. J Parkinsons Dis. 2015;5(3):581-94. doi: 10.3233/JPD-150570 Data standards; collaboration; data integration; privacy; quantitative disease progression; regulatory science 26406139
Nonmotor Symptoms in Subjects Without Evidence of Dopaminergic Deficits. Sprenger FS; Seppi K; Djamshidian A; Reiter E; Nocker M; Mair K; Göbel G; Poewe W Mov Disord. 2015 Mar 15. doi: 10.1002/mds.26204. [Epub ahead of print] SWEDDs; nonmotor symptoms; orthostatic hypotension; autonomic dysfunction; hyposmia 25772612
Morphological alterations in the caudate, putamen, pallidum, and thalamus in Parkinson's disease. Garg A; Appel-Cresswell S; Popuri K; McKeown MJ; Beg MF Front Neurosci. 2015 Mar 31;9:101. doi: 10.3389/fnins.2015.00101. eCollection 2015. LDDMM; MRI; prediction; shape analysis; surface displacement; disease severity 25873854
Planning for selective amygdalohippocampectomy involving less neuronal fiber damage based on brain connectivity using tractography. Lee SH, Kim M, Park H. Neural Regen Res. 2015 Jul;10(7):1107-12. doi: 10.4103/1673-5374.160104. betweenness centrality; connectivity; diffusion tensor imaging; epilepsy; magnetic resonance imaging; nerve regeneration; network analysis; neural regeneration; neuronal fibers; selective amygdalohippocampectomy; temporal lobe surgery; tractography 26330834
Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. Qamhawi Z; Towey D; Shah B; Pagano G; Seibyl J; Marek K; Borghammer P; Brooks DJ; Pavese N Brain. 2015 Jul 23. pii: awv215. [Epub ahead of print] serotonin; SPECT; tremor; non-motor 26209314
Plasma Apolipoprotein A1 Associates With Age at Onset and Motor Severity in Early Parkinson's Disease Patients. Swanson CR; Berlyand Y; Xie SX; Alcalay RN; Chahine LM,;Chen-Plotkin AS Mov Disord. 2015 Jul 24. doi: 10.1002/mds.26290. [Epub ahead of print] apolipoprotein A1; biomarker 26207725
Longitudinal Study of Gray Matter Changes in Parkinson Disease Jia X, Liang P, Li Y, Shi L, Wang D, Li K. AJNR Am J Neuroradiol. 2015 Dec;36(12):2219-26. doi: 10.3174/ajnr.A4447. Epub 2015 Sep 10 structural MR imaging, voxel-based morphometry analysis, structural MR imaging 26359153
Ipsilateral deficits of dopaminergic neurotransmission in Parkinson's disease Kaasinen V. Ann Clin Transl Neurol. 2015 Dec 5;3(1):21-6. doi: 10.1002/acn3.268. eCollection 2016 Jan. 26783547
Unsupervised learning based feature extraction for differential diagnosis of neurodegenerative diseases: A case study on early-stage diagnosis of Parkinson disease. Singh G; Samavedham L; J. Neurosci. Methods 2015 Dec;256():30-40 26304693
Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI). Nalls MA; Keller MF; Hernandez DG; Chen L; Stone DJ; Singleton AB; Parkinson\'s Progression Marker Initiative (PPMI) investigators; Mov. Disord. 2015 Aug;(): 26268663
Patterns of Motor and Non-Motor Features in Medication-Naïve Parkinsonism Jain S; Park SY; Comer D Neuroepidemiolgoy. 2015 Aug;45(1):59-69. non-motor 26227734
Genome-wide variant by serum urate interaction in Parkinson's disease. Nazeri A; Roostaei T; Sadaghiani S; Chakravarty MM; Eberly S; Lang AE; Voineskos AN Ann Neurol. 2015 Aug 18. doi: 10.1002/ana.24504. [Epub ahead of print] 26284320
Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease. Zhang Y; Wu IW; Buckley S; Coffey CS; Foster E; Mendick S; Seibyl J; Schuff N Mov Disord. 2015 Apr 29. doi: 10.1002/mds.26251. [Epub ahead of print] MRI; diffusion tensor imaging; DTI; diffusion tensor tractography; nigrostriatal pathway 25920732
Computer-aided diagnosis of Parkinson's disease based on [(123)I]FP-CIT SPECT binding potential images, using the voxels-as-features approach and support vector machines. Oliveira FP; Castelo-Branco M J Neural Eng. 2015 Apr;12(2):026008. doi: 10.1088/1741-2560/12/2/026008. Epub 2015 Feb 24. DaTSCAN; binding potential; classification; automated image analysis; SPECT 25710187
Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease Liu R; Umbach DM; Peddada SD; Xu Z; Tröster AI; Huang X; Chen H Neurology. 2015 May 26;84(21):2107-15. doi: 10.1212/WNL.0000000000001609. Epub 2015 Apr 29. nonmotor symptoms; olfaction; cognition; anxiety; autonomic function; sleep 25925983
Initial cognitive decline is associated with cortical thinning in early Parkinson disease. Pereira JB; Svenningsson P; Weintraub D; Brønnick K; Lebedev A; Westman E; Aarsland D; Neurology. 2014 Jun 3;82(22):2017-25. doi: 10.1212/WNL.0000000000000483. Epub 2014 May 7. cortical thickness; thinning; mild cognitive impairment; MCI; atrophy; 24808018
Automatic classification and prediction models for early Parkinson’s disease diagnosis from SPECT imaging Prashanth R; Roy SD; Mandal PK; Ghoshd S Expert Syst Appl. 2014 June;41(7): 3333-3342 [Epub ahead of print] early diagnosis; SPECT imaging; single photon emission computed tomography; DaTSCAN; striatal binding ratio; SBR; support vector machine; SVM 23152757
REM Sleep Behavior and Motor Findings in Parkinson's Disease: A Cross-sectional Analysis Mahajan A; Rosenthal LS; Gamaldo C; Salas RE; Pontone GM; McCoy A; Umeh C; Mari Z Tremor Other Hyperkinet Mov (N Y). 2014 Jun 23;4:245. doi: 10.7916/D84B2ZDF. eCollection 2014. Movement Disorders Society-United Parkinson's Disease Rating Scale; motor findings; rapid eye movement sleep; RBD; MDS UPDRS-3; 25009765
Teaching Video NeuroImages: Spasmodic dysphonia preceding idiopathic parkinsonism. Hannah-Shmouni F; Matiello M; Russell DS; Hasbani MJ Neurology 2014 Feb;82(6):e55. spasmodic dysphonia; idiopathic parkinsonism; DaTscan; phonatory breaks; rest tremor 24514016
What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic? Kim D; Paik JH; Shin DW; Kim HS; Park CS; Kang JH Exp Neurobiol. 2014 Dec;23(4):352-64. doi: 10.5607/en.2014.23.4.352. Epub 2014 Dec 12. biomarker; cerebrospinal fluid; alpha-synuclein 25548535
Course of psychiatric symptoms and global cognition in early Parkinson disease de la Riva P; Smith K; Xie SX; Weintraub D Neurology. 2014 Sep 16;83(12):1096-103. doi: 10.1212/WNL.0000000000000801. Epub 2014 Aug 15. cognition; psychiatric symptoms; DRT; dopamine replacement therapy; neuropsychiatric symptoms; NPS 25128183
Parkinson's disease detection using olfactory loss and REM sleep disorder features Prashanth R; Roy SD; Mandal PK; Ghosh S Conf Proc IEEE Eng Med Biol Soc. 2014 Aug;2014:5764-7. doi: 10.1109/EMBC.2014.6944937. olfactory loss; sleep disorders; University of Pennsylvania Smell Identification Test; UPSIT; Rapid eye movement sleep Behavior Disorder Screening Questionnaire; RBDSQ; Support Vector Machine; SVM 25571305
Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. Lebedev AV; Westman E; Simmons A; Lebedeva A; Siepel FJ; Pereira JB; Aarsland D; Front Syst Neurosci. 2014 Apr;8:45. SPECT; cognition; dopamine; graph theory; modularity; nodal strength; resting state fMRI 24765065
Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease. Siepel FJ; Brønnick KS; Booij J; Ravina BM; Lebedev AV; Pereira JB; Grüner R; Aarsland D Mov Disord. 2014 Dec;29(14):1802-8. doi: 10.1002/mds.26051. Epub 2014 Oct 4. SPECT; [123I]FP-CIT; cognitive impairment; dopamine transporter; early cognitive decline 25284687
Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. Goldman JG; Stebbins GT; Leung V; Tilley BC; Goetz CG Parkinsonism Relat Disord. 2014 Nov;20(11):1135-9. doi: 10.1016/j.parkreldis.2014.08.001. Epub 2014 Aug 13. cognitive impairment; daytime sleepiness; fatigue; Movement Disorder Society-Unified Parkinson's Disease Rating Scale; MDS-UPDRS; night-time sleep problems 25150770
CSF a-synuclein improves diagnostic and prognostic performance of CSF tau and AB in Alzheimers disease Toledo JB; Korff A; Shaw LM; Trojanowski JQ; Zhang J Acta Neuropathol. 2013 Nov;126(5):683-97. Alzheimer’s disease; dementia with Lewy body; Cerebrospinal fluid; amyloid beta; tau; alpha-synuclein 23812319
Shape features as biomarkers in early Parkinson's disease Prashanth R; Roy SD; Ghosh S; Mandal PK Neural Engin. IEEE/EMBS Conf. 2013 Nov;doi: 10.1109/NER.2013.6695985:517,520 dopaminergic imaging; Single Photon Emission Computerized Tomography; SPECT; SWEDD; [123I]FP-CIT; biomarkers 27035571
Application of Texture Analysis to DAT SPEC Imaging: Relationship to Clinical Assessments Arman Rahmim, Yousef Salimpour, Saurabh Jain, Stephan Blinder, Ivan Klyuzhin, Gwenn Smith, Zoltan Mari, Vesna Sossi 2015 DAT SPEC, Progression y 27995072
Aberrant Cerebral Network Topology and Mild Cognitive Impairment in Early Parkinson's Disease Christine R. Swanson, Yosef Berlyand, Sharon X. Xie, Lama A. Chahine, and Alice S. Chen-Plotkin 2014 Cerebral Network, Cognitive Impairment 25950288
Clinical Variables and Biomarkers in Prediction of Cognitive Impairment in Patients With Newly Diagnosed Parkinson's Disease: a Cohort Study Schrag A, Weintraub D, Siddiqui U, Jichi F, Schott J 2015 CSF 27866858